Emergent BioSolutions (EBS) Cash from Operations Growth (3y) (2013 - 2026)
Emergent BioSolutions (EBS) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 35.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.55% |
| Mar 31, 2026 | 43.15% |
| Dec 31, 2025 | -5.75% |
| Sep 30, 2025 | 68.56% |
| Jun 30, 2025 | 106.62% |
| Mar 31, 2025 | 33.04% |
| Dec 31, 2024 | -30.91% |
| Sep 30, 2024 | 109.57% |
| Jun 30, 2024 | 53.25% |
| Mar 31, 2024 | -142.58% |
| Dec 31, 2023 | -49.28% |
| Sep 30, 2023 | -17.07% |
| Jun 30, 2023 | -42.51% |
| Mar 31, 2023 | -73.06% |
| Dec 31, 2022 | -8.74% |
| Sep 30, 2022 | -187.93% |
| Jun 30, 2022 | 24.19% |
| Mar 31, 2022 | -33.06% |
| Dec 31, 2021 | 58.46% |
| Sep 30, 2021 | -54.22% |